Dr. David L. Groteluschen, MD

  • Medford, WI
  • Medical oncologist
NPI1679538011PAC ID3971516519
Medicare services, 2024
557
Medicare patients, 2024
222
Part D claims, 2024
1,333
Publications
5
MIPS score, 2024
100
Practice address
135 S Gibson St, Medford, WI 54451
Practice phone
Call (715) 748-8100
Professional email
Get professional email
Personal email
Get personal email
Mobile number
Get mobile number
Social profiles

Primary practice

Aspirus Medford Hospital

Hospital · Medford, Wisconsin

See all 11 affiliations

Find Dr. Groteluschen's professional email, personal email and mobile number

Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.

View contacts for free

Dr. David L. Groteluschen is a medical oncologist in Medford, Wisconsin

Dr. Groteluschen practices at Aspirus Medford Hospital in Medford, Wisconsin, part of Aspirus.

Dr. Groteluschen's NPI, 1679538011, was assigned on April 19, 2006. Dr. Groteluschen graduated from University of Iowa, RJ & L Carver College of Medicine in 2001. Dr. Groteluschen holds Wisconsin license 44953.

NPI and contact details
Medicare PAC ID
3971516519
NPI enumeration date
April 19, 2006
NPI status
Active
Accepts Medicare assignment
Yes
Practice phone
(715) 748-8100
Professional email
Get email
Personal email
Get email
Mobile number
Get number
Sex
Male
Estimated age
51
Medical school graduation
2001

Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; Dmand AI Affiliation Data; and Doctors and Clinicians National Downloadable File (CMS)

Dr. David L. Groteluschen practices at Aspirus Medford Hospital in Medford, Wisconsin

Dr. Groteluschen's primary practice is Aspirus Medford Hospital, at 135 S Gibson St, Medford, WI 54451 in Taylor County. The practice phone is (715) 748-8100.

Source: Dmand AI Affiliation Data

Dr. David L. Groteluschen is affiliated with 7 sites of care and 4 medical groups

Dr. Groteluschen's primary practice is Aspirus Medford Hospital in Medford, Wisconsin, part of Aspirus. Dr. Groteluschen is also affiliated with HSHS St. Vincent Hospital. The medical group on file is OSF Multi-Specialty Group. Dmand AI also links Dr. Groteluschen to 4 more hospitals, 3 medical groups and 1 hospice, each named with a free account.

See all 11 affiliations for Dr. Groteluschen

Sources: Dmand AI Affiliation Data; and Dmand AI Org Hierarchy Data

Dmand AI tracks the EHR system at Dr. David L. Groteluschen's practice

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Groteluschen practices, 7 sites in all. Vendor and product names are available with a free account.

EHR by site
SiteEHR vendor and product
Aspirus Medford HospitalAvailable with a free account
+6 more sites and 3 medical groupsAvailable with a free account

Source: Dmand AI Technology Install Data

For health IT teams

See the EHR and IT leaders at every hospital where Dr. Groteluschen practices

Dmand AI maps EHR vendors, IT decision makers and buying committees across Aspirus and 6.2K+ hospitals, with verified contacts in the same login.

Dr. David L. Groteluschen is one of 73 medical oncologists in Wisconsin

Medical oncology is Dr. Groteluschen's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Groteluschen is licensed in Wisconsin.

Specialties and state licenses

  • Medical oncology, WisconsinPrimaryLicense 44953 · taxonomy 207RX0202X

Medical oncologists near Dr. Groteluschen

Counts of medical oncologists with a Dmand AI profile, by place and practice. Each opens the list.

Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks

Dr. David L. Groteluschen billed Medicare for 557 services in 2024

CMS data shows 557 Medicare services from Dr. Groteluschen across 6 procedure codes in 2024, for 222 Medicare patients. Medicare paid $48,337 for them.

Medicare services, 2024557
Medicare patients222
Paid by Medicare$48,337
Procedure codes6

Dr. Groteluschen's Medicare services by type, 2023 to 2024

  • 2023
  • 2024
Office and hospital visits
2023: 4742024: 473No change
Other services
2023: 02024: 84

Where Dr. Groteluschen's Medicare services took place, 2024

  • In an office48587%
  • In a facility7213%

Dr. Groteluschen compared with the Wisconsin median for medical oncologists, 2024

  • Dr. Groteluschen
  • Wisconsin median
Medicare services
557vs 32273% above
Medicare patients
222vs 12479% above
Part D claims
1,032vs 2214.7 times

Medians across 70 medical oncologists in Wisconsin with Dmand AI profiles that report each measure.

Dr. Groteluschen's most billed Medicare procedure codes, 2024

CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.

See all procedures by Dr. Groteluschen

Need commercial claims for Dr. Groteluschen?

Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Groteluschen and other medical oncologists in Wisconsin.

Book a meeting

Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks

Dr. David L. Groteluschen treated 222 Medicare patients in 2024, average age 74

CMS counts 222 Medicare patients who saw Dr. Groteluschen in 2024. The largest group is 65 to 74, with 111 patients. 75% of them have high blood pressure, and 68% have high cholesterol. 9% are also on Medicaid. Their average risk score is 2.16, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Groteluschen's median patient age at 72, with 51% women.

Medicare patients, 2024222
Average age74
Average risk score2.16
Also on Medicaid9%

Dr. Groteluschen's Medicare patients by age, 2024

Dr. Groteluschen's Medicare patients by sex, 2024

  • Women11853%
  • Men10447%

Chronic conditions among Dr. Groteluschen's Medicare patients, 2024

  1. High blood pressure75%
  2. High cholesterol68%
  3. Cancer49%
  4. Arthritis40%
  5. Ischemic heart disease38%
  6. Anxiety33%
  7. Chronic kidney disease32%
  8. Diabetes28%

Share of Medicare patients with each condition. A patient can have several.

Dr. Groteluschen's patients across all payers

Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.

Patient panel by age, all payers

Median age 72

Patient panel by sex, all payers

  • Women51%
  • Men49%

Sources: Dmand AI Patient Panel Data; and Medicare Physician & Other Practitioners - by Provider (CMS), 2024 data

Dr. David L. Groteluschen wrote 1,333 Medicare Part D claims in 2024

In 2024, Dr. Groteluschen wrote 1,333 Medicare Part D claims for 314 patients. 75% of them were for generic drugs. CMS names the drug for 1,032 of them, across 38 drugs with 11 or more claims each, at $3,012,303 in total drug cost. In 2023, CMS named 732 claims across 29 drugs.

Part D claims, 20241,333
Drugs named by CMS38
Total drug cost$3M
Part D patients314

Dr. Groteluschen's Part D claims by kind of drug, 2024

  • Generic998 claims75%
  • Brand-name335 claims25%

Dr. Groteluschen's most prescribed drugs by claims, 2024

CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.

Drug classes CMS tracks in Dr. Groteluschen's Part D claims, 2024

  • Opioids9%119 of 1,333 claims
  • Antibiotics5%64 of 1,333 claims
  • Antipsychotics, patients 65 and over1%19 of 1,333 claims

Share of all Part D claims for each drug class CMS reports on. Classes with no claims are left out.

Part D claims for drugs CMS names, 2023 to 2024

  • 2023
  • 2024
Claims for drugs CMS names
2023: 7322024: 1,03241%

Drugs named by CMS: 38 in 2024, 29 in 2023.

See all prescribing by Dr. Groteluschen

Sources: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026; and Medicare Part D Prescribers - by Provider (CMS), 2024 data

Dr. David L. Groteluschen scored 100 out of 100 in Medicare's MIPS program for 2024

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Groteluschen for performance year 2024, reported as part of a group. Dr. Groteluschen accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Accepts Medicare assignment
Yes

Dr. Groteluschen's MIPS scores, performance year 2024

  • 100of 100Final score
  • 97.2of 100Quality
  • 100of 100Promoting Interoperability
  • 40of 100Improvement Activities

Each score is out of 100. The final score weighs the categories CMS scored for this clinician.

Sources: Doctors and Clinicians National Downloadable File (CMS); and Clinician Public Reporting: Overall MIPS Performance (CMS), 2024 data, released September 10, 2026

For MedTech and pharma teams

Find medical oncologists like Dr. Groteluschen by procedure volume and prescribing

Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.

Dr. David L. Groteluschen has 5 publications on record

Dmand AI links 5 papers to Dr. Groteluschen, published from 2012 to 2017. 2012 was the busiest year, with 2. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Capecitabine and Deoxycytidine. Dr. Groteluschen's most frequent co-authors are Sam Joseph Lubner, MD, Daniel L. Mulkerin, MD and Ernie Porteza Balcueva, MD.

Papers5
Years published2012 to 2017

Dr. Groteluschen's papers by year, 2012 to 2017

Topics Dr. Groteluschen writes about most

  • Antineoplastic Combined Chemotherapy Protocols
  • Capecitabine
  • Deoxycytidine
  • Fluorouracil
  • Niacinamide
  • Organoplatinum Compounds
  • Pancreatic Neoplasms
  • Phenylurea Compounds

Dr. Groteluschen's most frequent co-authors

Recent publications by Dr. Groteluschen

See all 5 publications and co-authors

See who Dr. Groteluschen researches with

Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Groteluschen works with, so you can find a warm path to the right medical oncologists.

How network discovery works

Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage

Dr. David L. Groteluschen received $46 in industry payments from 2018 to 2023

CMS Open Payments shows 3 general payments to Dr. Groteluschen from 3 drug and device companies from 2018 to 2023. Education make up the largest share, 69% of the total. Merck Sharp & Dohme Corporation paid the most, $20.

General payments to Dr. Groteluschen by program year, 2018 to 2023

General payments to Dr. Groteluschen by kind, 2018 to 2023

$46in total
  • Education$3269%
  • Food and beverage$1431%

Companies that paid Dr. Groteluschen the most, 2018 to 2023

Share is of all general payments to this clinician.

See all payments to Dr. Groteluschen

Source: Open Payments (CMS), 2025 data, released July 7, 2026

Dr. David L. Groteluschen graduated from University of Iowa, RJ & L Carver College of Medicine

Dr. Groteluschen graduated from University of Iowa, RJ & L Carver College of Medicine in 2001.

  1. Medical schoolUniversity of Iowa, RJ & L Carver College of Medicine

Source: Dmand AI Professional Profile Data

Sources for Dr. David L. Groteluschen's profile data

Sources for the data on this page
Data on this pageSource
NPI, name, sex, specialty and licensesNPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data
Practice locations and phoneDmand AI Affiliation Data
Primary practice, affiliations and health systemDmand AI Affiliation DataDmand AI Org Hierarchy Data
Medicare services and procedure codesMedicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab)
State medians for the same specialtyDmand AI Peer Benchmarks
Medicare patients and the all-payer patient panelDmand AI Patient Panel DataMedicare Physician & Other Practitioners - by Provider (CMS) (opens in a new tab)
Part D prescribingMedicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)Medicare Part D Prescribers - by Provider (CMS) (opens in a new tab)
MIPS scores, telehealth, assignment and procedure percentilesDoctors and Clinicians National Downloadable File (CMS) (opens in a new tab)Clinician Public Reporting: Overall MIPS Performance (CMS) (opens in a new tab)
Publications, topics and co-authorsPubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage
Industry paymentsOpen Payments (CMS) (opens in a new tab)
Training, board certification and membershipsDmand AI Professional Profile Data
EHR at each practice siteDmand AI Technology Install Data
Similar physiciansDmand AI Affiliation Data

Data last refreshed October 2026Report an inaccuracyRemove my information

FAQ

Frequently asked questions about Dr. David L. Groteluschen

Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.

What is Dr. David L. Groteluschen's NPI number?

Dr. David L. Groteluschen's NPI number is 1679538011. It was assigned on April 19, 2006, and it is active in the NPI Registry.

What kind of doctor is Dr. David L. Groteluschen?

Dr. David L. Groteluschen is a medical oncologist in Medford, Wisconsin. The primary specialty in the NPI Registry is Medical Oncology Physician (taxonomy code 207RX0202X).

Where does Dr. David L. Groteluschen practice?

Dr. Groteluschen practices at 135 S Gibson St, Medford, WI 54451. Dr. Groteluschen's primary practice is Aspirus Medford Hospital in Medford, Wisconsin, part of Aspirus. Dmand AI also links Dr. Groteluschen to 4 hospitals, 3 medical groups and 1 hospice.

What is Dr. David L. Groteluschen's office phone number?

The practice phone on file for Dr. Groteluschen is (715) 748-8100.

What is Dr. David L. Groteluschen's medical license number?

Dr. Groteluschen holds Wisconsin license 44953.

Which hospitals is Dr. David L. Groteluschen affiliated with?

Dr. Groteluschen practices at Aspirus Medford Hospital in Medford, Wisconsin. Dr. Groteluschen is also affiliated with HSHS St. Vincent Hospital. Dmand AI links Dr. Groteluschen to 4 more hospitals.

What medical group is Dr. David L. Groteluschen part of?

Dr. Groteluschen is linked to OSF Multi-Specialty Group. Dmand AI links Dr. Groteluschen to 3 more medical groups.

Does Dr. David L. Groteluschen accept Medicare?

Yes. CMS data shows Dr. Groteluschen billed Medicare for 557 services in 2024, and Dr. Groteluschen accepts Medicare assignment.

What is Dr. David L. Groteluschen's MIPS score?

Dr. Groteluschen's MIPS final score for performance year 2024 is 100 out of 100, reported as part of a group.

How many Medicare patients does Dr. David L. Groteluschen see?

CMS counts 222 Medicare patients who saw Dr. Groteluschen in 2024, with an average age of 74.

Show 7 more questionsShow fewer questions

What services does Dr. David L. Groteluschen bill to Medicare?

In 2024, Dr. Groteluschen's most billed Medicare services were office visit, established patient (99215), office visit, established patient (99214) and medicare service (G2211).

Where did Dr. David L. Groteluschen go to medical school?

Dr. Groteluschen graduated from University of Iowa, RJ & L Carver College of Medicine in 2001.

What drugs does Dr. David L. Groteluschen prescribe most?

In 2024 Medicare Part D data, Dr. Groteluschen's most prescribed drugs by claims were Ondansetron HCl, Prednisone and Tamoxifen Citrate.

Has Dr. David L. Groteluschen received payments from drug or device companies?

CMS Open Payments shows $46 in general payments to Dr. Groteluschen from 3 companies from 2018 to 2023. The largest total came from Merck Sharp & Dohme Corporation.

How long has Dr. David L. Groteluschen been practicing?

Dr. Groteluschen graduated from medical school in 2001, 25 years ago.

Does Dr. David L. Groteluschen do research?

Dmand AI links 5 publications to Dr. Groteluschen, published from 2012 to 2017.

Who does Dr. David L. Groteluschen publish with?

Dr. Groteluschen's most frequent co-authors are Sam Joseph Lubner, MD (2 shared papers), Daniel L. Mulkerin, MD (2 shared papers) and Ernie Porteza Balcueva, MD (1 shared paper).

Selling to medical oncology practices?

See medical oncologists in Wisconsin by site of care and group

Find the practices, groups and hospitals they work with, and the right people to contact at each.

  • 30 days free
  • Self-serve
  • No credit card

Cookie settings

Turn each category on or off. Your choice is kept for 12 months and you can change it here at any time.

Necessary

Always on. Sign-in, security, downloads you asked for, your cookie choice, and the page that led to a signup.

View cookies (6)
  • dm_consentDmand AI. Your cookie choices and whether your browser sent a Global Privacy Control signal. 12 months.
  • dm_ft, dm_ltDmand AI. The first and the latest page you arrived on, with the date, so a signup is credited to the page that worked. 90 days, 30 days.
  • dm_fs, dm_lsDmand AI. The first and the latest source of a visit (a search engine, a campaign or the site that linked here). 90 days, 30 days.
  • dm_dl, dm_dl_okDmand AI. After you give an email address for a download, lets you download files without being asked again. 30 days.
  • Session and CSRF cookiesDmand AI (app.dmand.ai). Sign-in and form protection in the application. Session.
  • __cf_bm, cf_clearanceCloudflare. Tells people from automated traffic and keeps the site available. 30 minutes; cf_clearance while a security check is valid.

Analytics

On unless you turn it off. How pages are used, in aggregate, and recordings of how pages are used.

View cookies (6)
  • Google Tag ManagerGoogle. Loads the analytics and marketing tags that are on. Sets no cookie of its own and does not load when both categories are off. n/a.
  • _ga, _ga_<container-id>Google Analytics 4. Visits and page views in aggregate on dmand.ai. 2 years.
  • _clck, _clskMicrosoft Clarity. Recordings and heatmaps of how pages are used, with form fields masked. 1 year, 1 day.
  • CLID, MUID, ANONCHK, MR, SMMicrosoft (clarity.ms). Set by Microsoft when Clarity loads, to recognize a browser across sites that use Clarity. Up to 1 year.
  • None (cookieless)Ahrefs Analytics. Page views in aggregate. n/a.
  • ph_<project>_posthogPostHog. Product usage, errors and performance in app.dmand.ai, used to fix bugs and improve features. 365 days.

Marketing

On unless you turn it off, and always off when your browser sends a Global Privacy Control signal. A visitor identification service tells our sales team which companies and people visit.

View cookies (6)
  • _reb2buid, _reb2butkRB2B. Recognizes a returning browser for visitor identification. 360 days, 1 year.
  • _reb2bgeoRB2B. The location used to decide whether a visit can be identified. 20 days.
  • _reb2brefRB2B. The page or site that referred the visit. 15 days.
  • _reb2bfxf, _reb2btd, _reb2bliRB2B. Links the visit to an identified business profile. 1 month.
  • _reb2bresolveRB2B. Holds a match while it is being resolved. 2 days.
  • _reb2sessionID, _reb2bloadedRB2B. The current visit, and a guard against loading the script twice. 30 minutes, 1 second.

Functional

On unless you turn it off. Remembers choices such as a collapsed section.

View cookies (none today)